This struck me as a very political answer.  I had asked if I could have access to the same information that Third Eye was apparently made aware of in schedule 4.22....this is the answer I finally received, I'm guessing BDZ probably received the same response:

Resverlogix adheres to a high standard Disclosure Policy. The Company is in compliance with proper disclosure methods.

Regards,
Sarah

Of course I had to send a follow up.  I don't like it when the answer I'm given is for a question I didn't ask, I did not ask if Resverlogix adhere's to a high standard disclosure policy or if they're in compliance with proper disclosure methods, I already assume that to be the case.

This was my reply:

Sarah,

That strikes me as a very political answer.  The SEDAR filing related to the loan agreement with Third Eye states very explicitly that schedule 4.22 includes, as of the closing date, the following:  

(i) target sample size, (ii) current enrolment size, (iii) primary and secondary endpoints, (iv) list of participating sites; (v) average patient profile; (vi) description of drug, dosing, and route of administration; (vii) target duration of study and current status, (viii) target participation duration of patients; (ix) target events and events to-date; (x) target relative risk reduction and relative risk reduction to-date; (xi) events until interim analysis; (xii) assumed dropout rate and rate-to-date

I too would like to know what these particulars, in particular those I have bolded.  Is there anything that would preclude the company from supplying me with the same information that was given to Third Eye?  If that's the case, that the company is unable to fulfill my request, then I would simply like to know why.

Regards,